Skip to main content

Innovation. Clarity. Execution.  I  Portfolio

Portfolio.

Life-changing innovation

The companies in which we have invested since the year 2006 have discovered and developed, fourteen approved medicines and products to the benefit of patients, physicians and our investors.

View and filter our portfolio below

Filter

Acutus

Cardiac mapping system for AF

Agenus

Broad immunotherapy platform for cancer

ALETA

Transformative adoptive cell therapy

Algeta

Alpha-emitter anticancer agents

Alpha

Novel oligonucleotide chemistry platform

Amphista

Targeted Protein Degradation

Aravive

Therapies targeting survival pathways for cancer

Argá Medtech

Next Generation Cardiac Ablation

Arrakis

Small molecule modulators of RNA

Artax

Novel therapy for autoimmune disease

Aura

Novel therapies for ocular cancers

AviadoBio

Revolution in gene therapy for neurodegenerative disorders

Avila

Covalent small molecule platform

Axonics

Novel sacral neuromodulation system

Biocartis

Molecular diagnostics platform

CardiacAssist

Alpha-emitter anticancer agents

CardiAQ

Novel device for mitral valve replacement

Cardiokine

Cardio-renal drug development

Cellnovo

Micro insulin pump with connectivity

Centessa

Novel asset-centric pharmaceutical company

CN

Nicotine replacement e-cigarette

Conatus

Therapeutics for liver disease

Curve

Next-gen functional discovery platform

Eloxx

Ribosome Modulating Agents for Rare Disease

Emergent

Innovative vaccines and therapeutics

Epitopea

Next generation immunotherapies

EUSA

Trans-Atlantic specialty pharma company

F2G

Novel anti-fungal therapy

Highlight

Bridging the innate to adaptive immune response

Infinity

Chemical genomic-based drug discovery

Iterum

Novel oral antibiotic

Kandy

Therapeutics for Women’s Health

KuDos

DNA damage repair therapy

Levicept

Novel pain treatment for osteoarthritis

Micromet

Bi-specific antibodies

MiroBio

Immune cell regulation

Moximed

Novel device for treating osteoarthritis of the knee

Nalu

Novel spinal cord stimulation device

NeRRe

Pipeline of neurokinin antagonists

Orphalan

Rare disease company

Pheno

Remyelinating therapy development

PIC

Targeting oncogene translation

PowderMed

Needle-free vaccine delivery

Proximie

Best-in-class technology for connected surgical care

Rappta

Novel PP2A activators to treat cancer

Respivert

Novel therapies for respiratory disorders

Santarus

Speciality pharmaceuticals

SEP

European pharma focused on urology

Thiakis

Novel hormone treatment for obesity

Tridek-One

Novel approach for treatment of vasculitis

UniQure

Gene therapy for rare disease

Ventus

Innovative smoking cessation products

Wondr

Collaboration for the medical community

About

Leading Venture Investors
Learn More

Exit History

View Our Exit History
Learn More